Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2020-06-23 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于调整公司回购股份价格上限的公告
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the adjustment of the upper limit of the company's share repurchase price. It details the board meeting decisions, the rationale for the price adjustment, the progress of the share repurchase, and includes independent directors' and supervisory board opinions. The document focuses on the company's share buyback program, including price limits, quantities, and compliance with relevant laws and regulations. It does not contain financial statements or quarterly/yearly financial results, nor is it a transcript, presentation, or legal proceeding update. The content is clearly about a share repurchase price adjustment, which fits the category of Transaction in Own Shares (POS). The document length is under 5,000 characters but contains substantive information about the share repurchase plan and its adjustment, not merely an announcement of a report publication or a certification. Therefore, the correct classification is POS.
2020-06-23 Chinese
关于获得盐酸乐卡地平片药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the receipt of a drug registration approval for Levcadipine Hydrochloride Tablets from the National Medical Products Administration. It contains no financial data, no mention of financial results, no detailed financial statements, and no regulatory filings related to financial performance. The document is a regulatory announcement about a product approval, which does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is also not a report publication announcement since it does not mention any report being published or attached. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a product approval by a government agency, which does not fit other specific categories.
2020-06-22 Chinese
关于控股股东股权质押的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement regarding the pledge of shares by the controlling shareholder of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the number of shares pledged, the proportion of total shares, and confirms no impact on control or performance obligations. The document is titled as an announcement and contains no financial statements or report data. It is a typical disclosure of a shareholder's share pledge, which fits the category of Regulatory Filings (RNS) as it is a regulatory announcement about share pledge status and not a financial report or capital change announcement.
2020-06-19 Chinese
关于获得药品临床试验通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (625 characters) from Shenzhen Salubris Pharmaceuticals Co., Ltd. about receiving a clinical trial notification from the National Medical Products Administration. It discusses the approval to conduct clinical trials for a drug and mentions future steps and risks. There is no financial data, no mention of financial results, no detailed report, and no indication of a meeting or voting results. It is an official regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like Annual Report, Earnings Release, or Capital Update. The document is not a report itself but an announcement of a regulatory event.
2020-06-16 Chinese
关于控股股东股权质押及解除质押的公告
Capital/Financing Update Classification · 100% confidence The document is a formal announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the pledge and release of shares held by its controlling shareholder. It details the number of shares pledged and released, the dates, and the impact on shareholding percentages. The document is structured as a disclosure announcement about share pledges and releases, which is typical for capital structure updates. It does not contain financial statements, earnings data, or management discussion. The document length is 2475 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits the category of Capital/Financing Update (CAP).
2020-06-09 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, prices, compliance with regulations, and the company's plans to continue the buyback within the approved limits. The document is relatively short (1679 characters) and focuses on the progress update of a share buyback, not a full financial report or earnings release. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2020-06-01 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.